The expansion is part of Governor DeSantis' allocation of additional doses of the Moderna vaccine to be administered to individuals ages 65 and older.
Eligible individuals can make appointments using the online reservation system at publix.com/covidvaccine, with vaccinations starting Thursday, Jan. 14.
The announcement brings the total number of Publix pharmacies offering COVID-19 vaccinations to 105 in 12 counties.
Vaccinations are provided to eligible individuals, by appointment only, while supplies last, and at no cost to the individual. Customers with health insurance will need to bring their insurance card to their scheduled appointment.
Customers without health insurance will need to provide their driver's license or Social Security number.
This expansion comes after the company received and distributed its first shipment of vaccines.
Publix continues to communicate with the state of Florida and the other six states in its operating area to provide COVID-19 vaccinations as part of their distribution efforts.
Publix, the largest employee-owned company in the US with more than 225,000 associates, currently operates 1,264 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina and Virginia.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100